In this study, we modeled the effect of GPx2 loss- and gain-of-function on the mammary tumor phenotype using a vast array of BC models representing most of the molecular subtypes including luminal B, HER2-enriched, and TNBCs. Here, ERBB2 is linked to breast cancer.